Mallinckrodt Pharmaceuticals is a specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives.
Our strong ability to master and manage complexity is the key component in making high-quality products that provide value for patients. Mallinckrodt’s growing portfolio of specialty pharmaceuticals help treat a wide variety of health conditions. We invest in areas such as autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products.
People throughout the world count on Mallinckrodt products every day to help them lead healthier lives. That’s why we proudly stand by the three values we have held for 150 years: to produce quality products with the utmost integrity and unparalleled service in order to better serve the patients, customers and communities in which we live and work.
For more information, please visit mallinckrodt.com.
ASMD – Acid Sphingomyelinase (Niemann-Pick Type A/B & Type B)
EMA – European Medicines Agency (European equivalent of FDA)
ERT – Enzyme Replacement Therapy
FDA – United States Food and Drug Administration
HDAC – Histone Deacetylase Inhibitors
ICV – Intracerebroventricular
IND – Investigational New Drug
i-IND – Individual Investiational New Drug
IRB – Institutional Review Board
NICHD – National Institute of Child Health and Human Development
NIH – National Institutes of Health
NPC – Niemann-Pick Disease Type C Disease
TRND – Therapeutics for Rare and Neglected Diseases